P. Roy Vagelos
P. Roy Vagelos (born November 29, 1929), also known as Pindaros Roy Vagelos or Roy Vagelos, is an American physician and business executive, who served as CEO of Merck & Co. from 1985 to 1994. He is recognized for his contributions to the field of medicine and pharmacology, and his leadership in the pharmaceutical industry.
Early life and education[edit | edit source]
Vagelos was born in Westfield, New Jersey, to Greek immigrant parents. He attended the University of Pennsylvania, where he received a Bachelor of Arts in Biology in 1950. He then went on to receive his M.D. from Columbia University College of Physicians and Surgeons in 1954.
Career[edit | edit source]
After completing his medical training, Vagelos joined the National Institutes of Health (NIH) as a research scientist. He made significant contributions to the understanding of lipid metabolism and fatty acid biosynthesis during his time at the NIH.
In 1975, Vagelos joined Merck & Co., one of the world's largest pharmaceutical companies. He served as the head of research before becoming CEO in 1985. Under his leadership, Merck developed several groundbreaking drugs, including ivermectin, a treatment for river blindness, and lovastatin, the first statin drug for lowering cholesterol.
Philanthropy[edit | edit source]
Vagelos and his wife, Diana, have been generous philanthropists, particularly in the field of education. They have made significant donations to the University of Pennsylvania and Columbia University, including a $250 million gift to Columbia's medical school, which was renamed in his honor as the Columbia University Roy and Diana Vagelos College of Physicians and Surgeons.
Awards and recognition[edit | edit source]
Vagelos has received numerous awards for his contributions to medicine and the pharmaceutical industry, including the Prince Mahidol Award for Medicine in 1996 and the National Medal of Technology and Innovation in 1999.
See also[edit | edit source]
- Merck & Co.
- Columbia University College of Physicians and Surgeons
- University of Pennsylvania
- National Institutes of Health
References[edit | edit source]
External links[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
